Arbutus Biopharma Corp (ABUS)

Currency in USD
3.400
+0.050(+1.49%)
Closed·
3.4000.000(0.00%)
·

ABUS Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
0.01 / -0.04
Revenue / Forecast
10.74M / 1.61M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
09/2025--/-0.045--/1.57M----Free Sign Up
06/20250.01/-0.0410.74M/1.61M+125%+567.08%Free Sign Up
03/2025-0.13/-0.11.76M/1.77M-30%-0.56%Free Sign Up
12/2024-0.07/-0.0861.57M/1.58M+18.6%-0.63%Free Sign Up
09/2024-0.1/-0.0941.34M/1.86M-6.38%-27.96%Free Sign Up
06/2024-0.11/-0.11.73M/1.77M-10%-2.26%Free Sign Up
03/2024-0.1/-0.11.53M/4.51M0%-66.08%Free Sign Up
12/2023-0.12/-0.122.14M/2.14M0%0%Free Sign Up
09/2023-0.12/-0.114.66M/4.75M-9.09%-1.89%Free Sign Up
06/2023-0.1/-0.114.65M/6.18M+9.09%-24.76%Free Sign Up

All numbers in USD

Arbutus Biopharma Corp Earnings Call Summary for Q2/2024

  • Positive Phase 2a data for imdusiran in hepatitis B treatment; Phase 2b development planned
  • 40% workforce reduction to streamline operations and extend cash runway through Q4 2026
  • $148.5 million cash balance; sufficient to fund upcoming Phase 2b trial
  • Litigation update: trial with Moderna and Pfizer/BioNTech set for April 21, 2025
  • Considering focus on patients with baseline HBsAg levels below 1,000 for higher response rates
Last Updated: 01/08/2024, 21:50
Read Full Transcript

FAQ

What Is Arbutus Biopharma's Earnings Per Share (TTM)?

The Arbutus Biopharma EPS (TTM) is -0.29.

When Is The Next Arbutus Biopharma Earnings Date?

Arbutus Biopharma will release its next earnings report on 04 Nov 2025.

What Is Arbutus Biopharma’s Revenue Forecasts For Upcoming Quarters?

Arbutus Biopharma’s revenue forecast is 1.57M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.